Fundz

Tissium Raises €50M In Series C Financing To Propel Its Platform To Commercial Stage

PRIVATEAug 31, 2021

Amount Raised

€50 Million

Round Type

Series C

ParisManufacturingBiotechnology

Description

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series C round of financing, raising €50 million from new and existing international investors. Cathay Health, affiliated to global investment firm Cathay Capital, led new investors and joined other institutional and individual backers while existing shareholders were led by Sofinnova Partners, a historical cornerstone investor, reinforcing TISSIUM shareholding structure. As part of the financing, Cathay Health Co-founder and Managing Partner Hongjie Hu will be joining TISSIUM’s board of directors.

Quick answer

TISSIUM raised €50 Million in a Series C round, dated August 31, 2021. TISSIUM is based in Paris, Ile-de-France, France.

How much did TISSIUM raise?
TISSIUM raised €50 Million in a Series C round on August 31, 2021.
What does TISSIUM do?
TISSIUM, a privately-owned MedTech company based in Paris, France and Boston, USA, is dedicated to the development and commercialization of products derived from its unique biopolymer platform.
Where is TISSIUM based and how big is it?
TISSIUM is based in Paris, Ile-de-France, France.

Source: Fundz verified event record.

Who else raised in Manufacturing and Biotechnology around the same time

Companies in the same sectors as TISSIUM that raised within 45 days of this round, from Fundz verified event records.

  • TendoNova raised $170K (Seed) on October 7, 2021.
  • Ensysce Biosciences raised $5.3M on October 6, 2021.
  • PMGC Holdings Inc. raised $732K (Seed) on October 1, 2021.
  • PMGC Holdings Inc. raised $139K (Pre-Seed) on October 1, 2021.
  • THE TRŪ® SHRIMP COMPANIES raised $350K (Seed) on September 29, 2021.
  • Nusano raised $48M on September 23, 2021.

Who to call at TISSIUM, and when

A new round usually means TISSIUM is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day TISSIUM raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at TISSIUM, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at TISSIUM. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

TISSIUM

Location

Paris, Ile-de-France, France

About

TISSIUM, a privately-owned MedTech company based in Paris, France and Boston, USA, is dedicated to the development and commercialization of products derived from its unique biopolymer platform. The company's products will address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction. TISSIUM is developing a portfolio of products that leverage its proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are the foundation of the company's technology platform. Currently, the Company has a pipeline of seven products across three verticals, including sutureless nerve repair, hernia repair and cardiovascular sealants. Each product is designed to enhance the tissue reconstruction process in a unique way. In addition, the company develops complementary delivery and activation devices for enhanced performance and usability of its products. TISSIUM's technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital), who co-founded the company in 2013. For more information, please visit: www.TISSIUM.com Follow us on LinkedIn, Twitter @TISSIUMtech. ### CONTACTS

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment TISSIUM raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for TISSIUM's next move

See what Strategic adds

TISSIUM raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.